As pharmaceutical R&D services increasingly rely on structural biology and AI-driven platforms, contract research organizations are consolidating capabilities to offer more integrated solutions. Pharmaron Beijing Co., Limited has entered into an agreement to acquire 82.54% equity interest in Biortus Biosciences […]
Pharmaron Acquires Biortus to Expand Structural Biology Capabilities Read More »
Delivering therapeutic cargo to kidney cells has long been considered one of the most difficult challenges in drug delivery. Helex recently announced an oversubscribed $3.5 million seed round to advance its non-viral gene therapy approach for genetic kidney diseases, bringing
Helex Secures $3.5M Seed Funding for Kidney-Targeted Gene Therapy Read More »
At the end of October, WELLSTAR Technologies, a majority-owned subsidiary of WELL Health Technologies Corp., announced an approximately C$62 million Series B preferred share investment at C$1.50 per share, expected to close in early December 2025. On November 20th, WELL
WELLSTAR Technologies Secures $62M Series B Financing Ahead of Planned 2026 Spinout Read More »
Prenatal testing for inherited genetic conditions typically requires invasive procedures that carry some risk to the pregnancy. Natera announced it will expand its Fetal Focus noninvasive test from five genes to 20 genes, with plans to launch the expanded panel
Natera Expands Prenatal Testing Panel to Cover 20 Inherited Conditions Read More »
Post-thrombotic syndrome affects an estimated 20 to 50% of patients after proximal deep vein thrombosis, with severe cases in 5 to 10% of patients. Venous in-stent restenosis—a narrowing of veins where stents have been placed—poses treatment challenges for patients with
InterVene Receives FDA Clearance for Venous Thrombectomy System Read More »
Patients with metastatic lung cancer and low PD-L1 expression face limited targeted treatment options in the first-line setting, with current standard care relying on immunotherapy combined with traditional chemotherapy. Daiichi Sankyo and AstraZeneca have initiated the DESTINY-Lung06 phase 3 trial,
Elderly heart attack patients face complex risk profiles that traditional scoring systems struggle to assess accurately. Researchers at Tehran Heart Center have developed machine learning models that significantly outperform conventional risk stratification tools, potentially enabling more personalized care for this
Machine Learning Models Achieve 95% AUC in Predicting Heart Complications Read More »
Medication errors in intensive care units occur at alarming rates, with unintended adverse drug events affecting 5% of hospitalized patients annually and contributing to doubled mortality risk. A multi-institutional research team led by the University of Georgia has developed PharmacyGPT,
University of Georgia Tests AI Framework for Intensive Care Medication Decision Support Read More »
Detecting Alzheimer’s disease early remains challenging, as current methods require invasive procedures or expensive centralized equipment unsuitable for widespread screening. Researchers at the University of Naples Federico II have developed a cost-effective electrochemical sensor that detects beta-amyloid peptides directly in
As mental health treatment developers seek funding to advance clinical programs through late-stage trials, psychedelic medicine companies face particular scrutiny over their path to commercialization. Cybin Inc., a Toronto-based neuropsychiatry company, recently closed a $175 million registered direct offering to
Cybin Secures $175M to Advance Psychedelic Depression Trials Read More »
